A bit misleading newB. The $153m (plus ongoing royalties) was actually for a portfolio of women's health products from MD Therapeutics when they had to offload these products after they ran into a debt problem followed by a failed $177m bailout from a private equity firm. The products included Imvexxy, Bijuva, Annovera and a range of other women's health products. The range is a great synergistic fit for Mayne and they should be able to grow the value of the products which had produced $64m in net revenue in 2022 for MD Therapeutics.
A bit misleading newB. The $153m (plus ongoing royalties) was...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.70 |
Change
-0.150(3.09%) |
Mkt cap ! $399.8M | |||
| Open | High | Low | Value | Volume |
| $4.88 | $5.08 | $4.63 | $830.6K | 170.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10095 | $4.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.71 | 305 | 5 |
View Market Depth
| Last trade - 14.19pm 21/10/2024 (20 minute delay) ? |
| MYX (ASX) Chart |